Company Directory - Research & Development
TOLREMO’s drug candidates aim to complement standard cancer therapies to offer better response rates, longer survival and an improved quality of life. In addition to combination therapies, we investigate our drug candidates for having efficacy as stand-alone agents in cancer indications of defined transcriptomes.
Originally founded in 1998 as an independent entity by Horst Lindhofer, we have assisted in the preclinical and clinical development of all Triomab® antibodies that are under development or received market approval, including that of Removab®, the first bispecific, trifunctional antibody on the market worldwide.
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide.
Our Founder, Dr. Suzanne Ildstad, has spent much of her career researching and developing novel approaches to induce immune tolerance in organ transplant recipients, and to enable safer, allogeneic stem cell transplant procedures between mismatched donor-recipient pairs. Over the course of this 30 year journey, many additional dedicated scientists, clinicians and patients have helped us get to where we are today.
Theragnostics, a private biotech company based in UK and US, is developing innovative radiopharmaceuticals to improve cancer diagnosis and treatment.
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies.
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
VSY Biotechnology GmbH is an innovation driven company with its progressive R&D activities in ophthalmology, orthopedics, aesthetics and biotechnologic drugs. VSY Biotechnology focuses on developing, designing and manufacturing superior state-of-the-art products to serve doctors, patients and consumers beyond their expectations.
VTR Biotech is a global science-driven biotechnology company founded in 1991, specialized in biological enzyme solutions, plant extracts, animal nutrition and health, aimed at promoting a more sustainable way of living.
Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today and the only single-shot chikungunya vaccine candidate.
We are a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Veeprho is Certified Pharmaceutical Impurity Reference Standards Supplier and Manufacturer in Europe, USA, UK. We are involved in the research, development, and distribution of synthesized impurities, metabolites, intermediates, and custom synthesis.
We aim to improve health and quality of life for the millions of people affected by chronic respiratory diseases. Our first-in-class development candidate, ensifentrine (RPL554), has the potential to provide relief for patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), COVID-19, cystic fibrosis (CF) and asthma.
Versantis is a clinical-stage biotech company developing transformative orphan drugs in liver and pediatric diseases. Founded by leading scientists from ETH Zurich and industry experts, Versantis' mission is to provide quality therapeutic solutions to revolutionize the critical care of cirrhosis decompensations and neonatal hyperammonemic crises.
Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. We are taking a multi-program, multi-technology platform approach, assembled through internal development, collaborations, and acquisitions.
